TITLE

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

AUTHOR(S)
Garrido, Federico; Algarra, Ignacio; García-Lora, Angel M.
PUB. DATE
October 2010
SOURCE
Cancer Immunology, Immunotherapy;Oct2010, Vol. 59 Issue 10, p1601
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The discovery of tumor antigens recognized by T lymphocytes has stimulated the development of a variety of cancer treatment protocols aimed at enhancing antitumor-specific T cell responses and tumor rejection. However, immunotherapy-mediated regression of established tumors and clearly positive clinical response to such treatment has not been achieved yet despite the induction of T cells directed against tumor antigens. The failure of the modern immunotherapy protocols can be explained by different tumor escape mechanisms that have been defined in various types of malignancy. The loss or downregulation of MHC class I antigens in tumor cells is one of the best analyzed mechanisms. In this review, we show experimental evidence obtained in our laboratory on human tumors and in a mouse cancer model suggesting that the molecular mechanism responsible for the MHC class I alteration in tumor cells might have a crucial impact on tumor recovery of normal H-2/HLA expression during the natural history of tumor development or after immunotherapy. When the preexisting molecular lesion underlying tumor MHC class I alteration is reversible (regulatory or soft), class I expression can be recovered leading to regression of tumor lesion. In contrast, if the HLA class I alteration is irreversible in nature (structural or hard), the lesion will progress killing the host. This is a new vision of the role of MHC class I alteration in tumors that can explain the failure of immunotherapy in a variety of different clinical protocols.
ACCESSION #
52449796

 

Related Articles

  • In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Vries, I. J. M.; Bernsen, M. R.; van Geloof, W. L.; Scharenborg, N. M.; Lesterhuis, W. J.; Rombout, P. D. M.; Van Muijen, G. N. P.; Figdor, C. G.; Punt, C. J. A.; Ruiter, D. J.; Adema, G. J. // Cancer Immunology, Immunotherapy;Oct2007, Vol. 56 Issue 10, p1667 

    Application of tetrameric MHC class I-peptide complexes has significantly improved the monitoring of antigen-specific T cell immune responses in mouse models as well as in clinical studies. Especially MHC class I tetramer analysis of tumor-specific T cells in suspension or on thick vibratome...

  • TCR–peptide–MHC interactions in situ show accelerated kinetics and increased affinity. Huppa, Johannes B.; Axmann, Markus; Mörtelmaier, Manuel A.; Lillemeier, Björn F.; Newell, Evan W.; Brameshuber, Mario; Klein, Lawrence O.; Schütz, Gerhard J.; Davis, Mark M. // Nature;2/18/2010, Vol. 463 Issue 7283, p963 

    The recognition of foreign antigens by T lymphocytes is essential to most adaptive immune responses. It is driven by specific T-cell antigen receptors (TCRs) binding to antigenic peptide–major histocompatibility complex (pMHC) molecules on other cells. If productive, these interactions...

  • Detection and Characterization of Cellular Immune Responses Using Peptide --MHC Microarrays. Soen, Yoav; Chen, Daniel S.; Kraft, Daniel L.; Davis, Mark M.; Brown, Patrick O. // PLoS Biology;Dec2003, Vol. 1 Issue 3, p429 

    The detection and characterization of antigen-specific T cell populations is critical for understanding the development and physiology of the immune system and its responses in health and disease. We have developed and tested a method that uses arrays of peptide-MHC complexes for the rapid...

  • High Efficiency of Antiviral CD4+ Killer T Cells. Hildemann, Steven K.; Eberlein, Jens; Davenport, Bennett; Nguyen, Tom T.; Victorino, Francisco; Homann, Dirk // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    The destruction of infected cells by cytotxic T lymphocytes (CTL) is integral to the effective control of viral and bacterial diseases, and CTL function at large has long been regarded as a distinctive property of the CD8+T cell subset. In contrast, and despite their first description more than...

  • CD4 T cells in tumor immunity. Gerloni, Mara; Zanetti, Maurizio // Springer Seminars in Immunopathology;Jun2005, Vol. 27 Issue 1, p37 

    T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in...

  • The 'chop-and-change' of MHC class I assembly. Elliott, Tim // Nature Immunology;Jan2006, Vol. 7 Issue 1, p7 

    This article states that the CD8+ T cell recognition of peptides presented by major histocompatibility complex class I molecules is essential for effective antiviral and antitumor immune responses. Cytotoxic T lymphocytes scan a micro-array of peptide-major histocompatibility complex class I...

  • IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Regis, G.; Icardi, L.; Conti, L.; Chiarle, R.; Piva, R.; Giovarelli, M.; Poli, V.; Novelli, F. // Leukemia (08876924);Nov2009, Vol. 23 Issue 11, p2102 

    STAT1 and STAT3 are the main mediators of the signaling of interferons (IFNs) and of gp130 cytokines, respectively. Neoplastic T lymphocytes frequently become resistant to the IFN-γ/STAT1 apoptotic pathway, often because of the downregulation of the IFN-γR2 receptor chain. Many studies...

  • Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs. Zaheer-ul-Haq; Khan, Waqasuddin // Journal of Computer-Aided Molecular Design;Jan2011, Vol. 25 Issue 1, p81 

    Class II major histocompatibility complex (MHC II) molecules as expressed by antigen-presenting cells are heterodimeric cell-surface glycoprotein receptors that are fundamental in initiating and propagating an immune response by presenting tumor-associated antigenic peptides to CD4/T cells. The...

  • NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+ FOXP3+ Treg Compartment. Redjimi, Nassima; Duperrier-Amouriaux, Karine; Raimbaud, Isabelle; Luescher, Immanuel; Dojcinovic, Danijel; Classe, Jean-Marc; Berton-Rigaud, Dominique; Frene, Jean-Sébastien; Bourboulox, Emmanuelle; Valmori, Danila; Ayyoub, Maha // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Spontaneous CD4+ T-cell responses to the tumor-specific antigen NY-ESO-1 (ESO) are frequently found in patients with epithelial ovarian cancer (EOC). If these responses are of effector or/and Treg type, however, has remained unclear. Here, we have used functional approaches together with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics